A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin with Atezolizumab (MPDL3280A) in Patients with Metastatic and Muscle Invasive Bladder Cancer, Respectively

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

28 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
28 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
01 May 2023 Results of the perioperative outcomes of the GC+A cohort compared to a matched cohortof patients with MIBC who received GC, presented at the 118th Annual Meeting of the American Urological Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com